Risk Factors for Hypoglycaemia in Acute Gastroenteritis in Children Under Five Years of Age
Abstract
Acute gastroenteritis (AGE) in children is one of the leading health problems, especially in developing countries. Objective: To find the frequency of hypoglycemia in Acute Gastroenteritis in children under five years of age. Methods: This Descriptive case series was conducted at the Pediatrics Medical Emergency Department, Children Hospital, and the University of Child Health Sciences Lahore from November 2024 till May 2025. Data were collected through a Non-probability consecutive sampling technique. Results: Data were collected from 200 patients. The results show no significant difference in mean age, gender distribution, or sex proportions between cases and controls, as indicated by p-values >0.05. However, mean weight was significantly lower in cases (12.4 ± 2.1 kg) compared to controls (13.5 ± 2.0 kg), with a p-value <0.05. Additionally, mean blood glucose levels were significantly lower in cases (48.3 ± 7.5 mg/dL) than in controls (85.7 ± 12.4 mg/dL), with a highly significant p-value <0.001. No dehydration was observed in only 5% of cases compared to 25% of controls, with a p-value <0.01. Severe dehydration was significantly higher in cases (30%) than in controls (10%), with a highly significant p-value <0.001. Conclusion: It is concluded that severe dehydration and severe malnourishment are important risk factors associated with the condition under study.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 200 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.